MOSCOW--(BUSINESS WIRE)--Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica, a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates. The partnership involves joint investment in advanced medical technologies and late stage innovative drugs for their development, manufacture and commercialization, including the creation of a GMP production facility in Russia. Mr. Egros has more than 20 years of international experience of work in the pharmaceutical industry. Prior to coming to NovaMedica he held managerial positions at Xanodyne, UCB (in Belgium, the USA and Japan). Fabrice also worked in others pharmaceutical companies, as Parke-Davis/Warner Lambert in Germany and the USA, Sanofi-Aventis in Japan and the USA. His responsibilities have encompassed Clinical development, marketing, market access, sales, Business development and general management functions Fabrice received his Pharm D and Ph.D in pharmaceutical sciences degrees at Chatenay Malabry University (Paris, France), a diploma in business administration from Schiller International University (Dunedin, Florida, USA). Besides that he studied Advanced Management Program at Harvard University (Cambridge, Massachusetts, USA).
